{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:57:51Z","timestamp":1793429871051,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2415-14-161","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T03:04:57Z","timestamp":1434596697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and tolerability of fixed-combination bimatoprost\/timolol versus fixed-combination dorzolamide\/brimonidine\/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study"],"prefix":"10.1186","volume":"14","author":[{"given":"Alfonso","family":"Garc\u00eda-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A","family":"Paczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Jim\u00e9nez-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Hartleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,19]]},"reference":[{"issue":"3","key":"527_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006, 90 (3): 262-267. 10.1136\/bjo.2005.081224.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"527_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/ICU.0b013e3283360b1e","volume":"21","author":"E Kim","year":"2010","unstructured":"Kim E, Varma R: Glaucoma in Latinos\/Hispanics. Curr Opin Ophthalmol. 2010, 21 (2): 100-105. 10.1097\/ICU.0b013e3283360b1e.","journal-title":"Curr Opin Ophthalmol"},{"issue":"12","key":"527_CR3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/archopht.119.12.1819","volume":"119","author":"HA Quigley","year":"2001","unstructured":"Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R: The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001, 119 (12): 1819-1826. 10.1001\/archopht.119.12.1819.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"527_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ajo.2012.02.014","volume":"154","author":"R Varma","year":"2012","unstructured":"Varma R, Wang D, Wu C, Francis BA, Nguyen BB, Chopra V, Memarzadeh F, Torres M, Azen SP, Los Angeles Latino Eye Study Group: Four-year incidence of open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2012, 154 (2): 315-325 e311. 10.1016\/j.ajo.2012.02.014.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"527_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archopht.120.6.714","volume":"120","author":"MO Gordon","year":"2002","unstructured":"Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Kass MA: The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002, 120 (6): 714-720. 10.1001\/archopht.120.6.714. discussion 829\u2013830","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"527_CR6","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ophtha.2012.05.030","volume":"119","author":"X Jiang","year":"2012","unstructured":"Jiang X, Varma R, Wu S, Torres M, Azen SP, Francis BA, Chopra V, Nguyen BB, Los Angeles Latino Eye Study Group: Baseline risk factors that predict the development of open-angle glaucoma in a population: the Los Angeles Latino Eye Study. Ophthalmology. 2012, 119 (11): 2245-2253. 10.1016\/j.ophtha.2012.05.030.","journal-title":"Ophthalmology"},{"issue":"4","key":"527_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998, 126 (4): 487-497.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"527_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","volume":"126","author":"BC Chauhan","year":"2008","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE, Canadian Glaucoma Study Group: Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008, 126 (8): 1030-1036. 10.1001\/archopht.126.8.1030.","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"527_CR9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M, Early Manifest Glaucoma Trial Group: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002, 120 (10): 1268-1279. 10.1001\/archopht.120.10.1268.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"527_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/00055735-200404000-00008","volume":"15","author":"MC Leske","year":"2004","unstructured":"Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E: Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol. 2004, 15 (2): 102-106. 10.1097\/00055735-200404000-00008.","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"527_CR11","first-page":"5","volume":"38","author":"B Chae","year":"2013","unstructured":"Chae B, Cakiner-Egilmez T, Desai M: Glaucoma medications. Insight. 2013, 38 (1): 5-9. quiz 10","journal-title":"Insight"},{"issue":"9","key":"527_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2165\/00002512-200825090-00002","volume":"25","author":"CA Webers","year":"2008","unstructured":"Webers CA, Beckers HJ, Nuijts RM, Schouten JS: Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008, 25 (9): 729-759. 10.2165\/00002512-200825090-00002.","journal-title":"Drugs Aging"},{"issue":"1","key":"527_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002512-200522010-00001","volume":"22","author":"RE Marquis","year":"2005","unstructured":"Marquis RE, Whitson JT: Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005, 22 (1): 1-21. 10.2165\/00002512-200522010-00001.","journal-title":"Drugs Aging"},{"issue":"1","key":"527_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","volume":"135","author":"RS Noecker","year":"2003","unstructured":"Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, The Bimatoprost\/Latanoprost Study Group: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003, 135 (1): 55-63. 10.1016\/S0002-9394(02)01827-5.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"527_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu WP, XLT Study Group: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003, 135 (5): 688-703. 10.1016\/S0002-9394(03)00098-9.","journal-title":"Am J Ophthalmol"},{"issue":"1 Suppl","key":"527_CR16","first-page":"S20","volume":"14","author":"SJ McKinnon","year":"2008","unstructured":"McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ: Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008, 14 (1 Suppl): S20-S27.","journal-title":"Am J Manag Care"},{"issue":"9","key":"527_CR17","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"MB Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM: Twice-daily 0.2% brimonidine\u20130.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006, 124 (9): 1230-1238. 10.1001\/archopht.124.9.1230.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"527_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1517\/14728214.12.2.313","volume":"12","author":"DF Woodward","year":"2007","unstructured":"Woodward DF, Chen J: Fixed-combination and emerging glaucoma therapies. Exp Opin Emerg Drugs. 2007, 12 (2): 313-327. 10.1517\/14728214.12.2.313.","journal-title":"Exp Opin Emerg Drugs"},{"issue":"4","key":"527_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1089\/jop.2012.0186","volume":"29","author":"L Quaranta","year":"2013","unstructured":"Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, Floriani I: Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocular Pharmacol Therap. 2013, 29 (4): 382-389. 10.1089\/jop.2012.0186.","journal-title":"J Ocular Pharmacol Therap"},{"issue":"12","key":"527_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2165\/00002512-200724120-00004","volume":"24","author":"AS Khouri","year":"2007","unstructured":"Khouri AS, Realini T, Fechtner RD: Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007, 24 (12): 1007-1016. 10.2165\/00002512-200724120-00004.","journal-title":"Drugs Aging"},{"issue":"3\u20134","key":"527_CR21","first-page":"174","volume":"41","author":"LM Baiza-Dur\u00e1n","year":"2009","unstructured":"Baiza-Dur\u00e1n LM, Alvarez-Delgado J, Contreras-Rubio AY, Medrano-Palafox J, De Luca-Brown A, Casab-Rueda H, Cort\u00e9s-Gast\u00e9lum MA, Garcidue\u00f1as-Mej\u00eda MJ, G\u00f3mez-Bastar P, Gil-Carrasco F, Hartleben-Matkin C, Jim\u00e9nez-Rom\u00e1n J, Moreno-Mar\u00edn ML, Paczka-Zapata JA, Velasco-Gallegos G, Vergara-Sinta M: The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial. Ann Ophthalmol (Skokie). 2009, 41 (3\u20134): 174-178.","journal-title":"Ann Ophthalmol (Skokie)"},{"key":"527_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2147\/OPTH.S33578","volume":"6","author":"LM Baiza-Dur\u00e1n","year":"2012","unstructured":"Baiza-Dur\u00e1n LM, Llamas-Moreno JF, Ayala-Barajas C: Comparison of timolol 0.5%\u2009+\u2009brimonidine 0.2%\u2009+\u2009dorzolamide 2% versus timolol 0.5%\u2009+\u2009brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2012, 6: 1051-1055.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"527_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/IJG.0b013e3181507313","volume":"17","author":"JD Brandt","year":"2008","unstructured":"Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, for the Ganfort Investigators Group II: Bimatoprost\/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008, 17 (3): 211-216. 10.1097\/IJG.0b013e3181507313.","journal-title":"J Glaucoma"},{"issue":"1","key":"527_CR24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/112067210901900110","volume":"19","author":"M Centofanti","year":"2009","unstructured":"Centofanti M, Oddone F, Vetrugno M, Manni G, Fogagnolo P, Tanga L, Ferreri P, Rossetti L: Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009, 19 (1): 66-71.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"527_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/0002512-200926020-00008","volume":"26","author":"MP Curran","year":"2009","unstructured":"Curran MP, Orman JS: Bimatoprost\/timolol: a review of its use in glaucoma and ocular hypertension. Drugs Aging. 2009, 26 (2): 169-184. 10.2165\/0002512-200926020-00008.","journal-title":"Drugs Aging"},{"issue":"4","key":"527_CR26","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1185\/03007990902816947","volume":"25","author":"C Feuerhake","year":"2009","unstructured":"Feuerhake C, Buchholz P, Kimmich F: Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Curr Med Res Opin. 2009, 25 (4): 1037-1043. 10.1185\/03007990902816947.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"527_CR27","first-page":"15","volume":"2","author":"ME Gheith","year":"2008","unstructured":"Gheith ME, Mayer JR, Siam GA, Monteiro de Barros DS, Thomas TL, Katz LJ: Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%). Clin Ophthalmol. 2008, 2 (1): 15-20.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"527_CR28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/112067210701700108","volume":"17","author":"A Hommer","year":"2007","unstructured":"Hommer A, Ganfort Investigators Group I: A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%\/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007, 17 (1): 53-62.","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"527_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/IJG.0b013e3181bdb586","volume":"19","author":"RA Lewis","year":"2010","unstructured":"Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL, for the Ganfort Investigators Group II: The safety and efficacy of bimatoprost\/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010, 19 (6): 424-426. 10.1097\/IJG.0b013e3181bdb586.","journal-title":"J Glaucoma"},{"issue":"1","key":"527_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/14656566.9.1.137","volume":"9","author":"A Martinez","year":"2008","unstructured":"Martinez A, Sanchez M: Efficacy and safety of bimatoprost\/timolol fixed combination in the treatment of glaucoma or ocular hypertension. Exp Opin Pharmacother. 2008, 9 (1): 137-143. 10.1517\/14656566.9.1.137.","journal-title":"Exp Opin Pharmacother"},{"issue":"4","key":"527_CR31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/eye.2008.148","volume":"23","author":"A Martinez","year":"2009","unstructured":"Martinez A, Sanchez M: Bimatoprost\/timolol fixed combination vs latanoprost\/timolol fixed combination in open-angle glaucoma patients. Eye. 2009, 23 (4): 810-818. 10.1038\/eye.2008.148.","journal-title":"Eye"},{"issue":"4","key":"527_CR32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/112067210701700436","volume":"17","author":"AL Robin","year":"2007","unstructured":"Robin AL: A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%\/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007, 17 (4): 685-686. author reply 686\u2013687","journal-title":"Eur J Ophthalmol"},{"key":"527_CR33","volume-title":"Clinical Decisions in Glaucoma","author":"E Hodapp","year":"1993","unstructured":"Hodapp E, Parrish RK, Anderson DR: Clinical Decisions in Glaucoma. 1993, St. Louis, MO: The C.V. Mosby Co."},{"issue":"5","key":"527_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL: Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000, 118 (5): 615-621. 10.1001\/archopht.118.5.615.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"527_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ophtha.2007.01.036","volume":"115","author":"C Baudouin","year":"2008","unstructured":"Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, Brignole-Baudouin F: The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008, 115 (1): 109-115. 10.1016\/j.ophtha.2007.01.036.","journal-title":"Ophthalmology"},{"issue":"4","key":"527_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12325-013-0021-8","volume":"30","author":"S Lee","year":"2013","unstructured":"Lee S, Kim MK, Choi HJ, Wee WR, Kim DM: Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface. Adv Ther. 2013, 30 (4): 420-429. 10.1007\/s12325-013-0021-8.","journal-title":"Adv Ther"},{"issue":"4","key":"527_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C: Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Brit J Ophthalmol. 2002, 86 (4): 418-423. 10.1136\/bjo.86.4.418.","journal-title":"Brit J Ophthalmol"},{"issue":"4","key":"527_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2165\/11588830-000000000-00000","volume":"28","author":"JJ Servat","year":"2011","unstructured":"Servat JJ, Bernardino CR: Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011, 28 (4): 267-282. 10.2165\/11588830-000000000-00000.","journal-title":"Drugs Aging"},{"issue":"4","key":"527_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The AGIS Investigators","year":"2000","unstructured":"The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000, 130 (4): 429-440.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"527_CR40","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002, 120 (6): 701-713. 10.1001\/archopht.120.6.701. discussion 829\u2013830","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"527_CR41","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/archopht.120.10.1371","volume":"120","author":"PR Lichter","year":"2002","unstructured":"Lichter PR: Expectations from clinical trials: results of the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002, 120 (10): 1371-1372. 10.1001\/archopht.120.10.1371.","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"527_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/archophthalmol.2010.196","volume":"128","author":"BC Chauhan","year":"2010","unstructured":"Chauhan BC, Mikelberg FS, Artes PH, Balazsi AG, LeBlanc RP, Lesk MR, Nicolela MT, Trope GE, for the Canadian Glaucoma Study Group: Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol. 2010, 128 (10): 1249-1255.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"527_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/BF02849907","volume":"24","author":"S Dunker","year":"2007","unstructured":"Dunker S, Schmucker A, Maier H, Latanoprost\/Timolol Fixed Combination Study Group: Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007, 24 (2): 376-386. 10.1007\/BF02849907.","journal-title":"Adv Ther"},{"issue":"10","key":"527_CR44","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1185\/03007990903260129","volume":"25","author":"EJ Higginbotham","year":"2009","unstructured":"Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A: Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009, 25 (10): 2543-2547. 10.1185\/03007990903260129.","journal-title":"Curr Med Res Opin"},{"key":"527_CR45","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2147\/OPTH.S13074","volume":"4","author":"G Brief","year":"2010","unstructured":"Brief G, Lammich T, Nagel E, Pfennigsdorf S, Spraul CW, Ho S: Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment. Clin Ophthalmol. 2010, 4: 1125-1129.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"527_CR46","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/archopht.1995.01100020100038","volume":"113","author":"JM Tielsch","year":"1995","unstructured":"Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC: Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995, 113 (2): 216-221. 10.1001\/archopht.1995.01100020100038.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"527_CR47","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/archopht.1995.01100070092031","volume":"113","author":"MC Leske","year":"1995","unstructured":"Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP: Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995, 113 (7): 918-924. 10.1001\/archopht.1995.01100070092031.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"527_CR48","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0161-6420(00)00138-X","volume":"107","author":"L Bonomi","year":"2000","unstructured":"Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A: Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000, 107 (7): 1287-1293. 10.1016\/S0161-6420(00)00138-X.","journal-title":"Ophthalmology"},{"issue":"7","key":"527_CR49","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/archopht.120.7.954","volume":"120","author":"MC Leske","year":"2002","unstructured":"Leske MC, Wu SY, Nemesure B, Hennis A: Incident open-angle glaucoma and blood pressure. Arch Ophthalmol. 2002, 120 (7): 954-959. 10.1001\/archopht.120.7.954.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"527_CR50","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1167\/iovs.05-1253","volume":"47","author":"L Quaranta","year":"2006","unstructured":"Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, Gandolfo E: Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006, 47 (7): 2917-2923. 10.1167\/iovs.05-1253.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"527_CR51","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1167\/iovs.08-1744","volume":"49","author":"L Quaranta","year":"2008","unstructured":"Quaranta L, Miglior S, Floriani I, Pizzolante T, Konstas AG: Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Invest Ophthalmol Vis Sci. 2008, 49 (10): 4226-4231. 10.1167\/iovs.08-1744.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"527_CR52","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1177\/0091270011420254","volume":"52","author":"L Quaranta","year":"2012","unstructured":"Quaranta L, Katsanos A, Floriani I, Riva I, Russo A, Konstas AG: Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012, 52 (10): 1552-1557. 10.1177\/0091270011420254.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"527_CR53","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/31.1.140","volume":"31","author":"DR Elbourne","year":"2002","unstructured":"Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A: Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002, 31 (1): 140-149. 10.1093\/ije\/31.1.140.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"527_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2125.1979.tb05903.x","volume":"8","author":"M Hills","year":"1979","unstructured":"Hills M, Armitage P: The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979, 8 (1): 7-20. 10.1111\/j.1365-2125.1979.tb05903.x.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-14-161\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T22:20:33Z","timestamp":1548195633000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-14-161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-14-161","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"3 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"161"}}